MilliporeSigma Invests $20-M in Swiss Lab; Cytovance, Bionova Expand
The latest from CDMOs, CMOs, and suppliers featuring MilliporeSigma, Cytovance Biologics, and Bionova Scientific.
Biologics manufacturing
Cytovance Biologics Adds Mass Spec Services
Cytovance Biologics, an Oklahoma City, Oklahoma-based biologics contract manufacturer, has added in-house mass spectrometry services to its analytical development suite of services.
Cytovance invested in the Q Exactive HF-X Orbitrap by Thermo Scientific with a Vanquish UHPLC that is configured for a range of applications, including intact mass measurements, native protein analysis, peptide and post-translational modification analysis, and glycan analysis.
Source: Cytovance Biologics
Bionova Scientific Breaks Ground on New Biologics Mfg Center
Bionova Scientific, a Fremont, California-based biologics CDMO, has initiated construction of a new biologics manufacturing facility in Fremont. Construction is scheduled to be completed in approximately 10 months (as reported on July 9, 2020), with commissioning scheduled for the third quarter of 2021.
The 36,000-square-foot-facility will use single-use technologies for all core unit operations and is designed to accommodate two 2,000-L mammalian cell-culture trains for producing clinical and commercial bulk drug substance. Located within Bionova’s 56,000-square-foot-headquarters in Fremont, the plant is optimized for multi-product manufacturing of monoclonal antibodies and other recombinant proteins.
Bionova says it is currently in planning discussions with clients for production slots in 2021.
Source: Bionova Scientific
General
MilliporeSigma To Invest $20 M in Swiss Lab; Opens Center in China
MilliporeSigma has announced plans to build a new, $20-million laboratory facility in Buchs, Switzerland to support its reference-materials business and has opened a center in Shanghai, China to support drug discovery, development and manufacturing.
Completion of the three-story, 12,000-m2 Buchs building is scheduled for December 2021, and the move is planned for early 2022. The flexible workplace design includes laboratory and office space for 40 employees in research and development, analytical production and quality control. The laboratory area can be adapted to new requirements in the future, including increased site capacity.
In addition, MilliporeSigma has opened an M Lab Collaboration Center in Shanghai, China with a total lab size of approximately 10,000 m2. The center, which is the largest on nine M Lab Collaboration Centers, includes pilot-scale and process-development support labs and provides product demonstrations, training, formal bioprocessing educational courses and experiments as well as best practices for developing, optimizing, and scaling up processes and simplifying technology transfer.
Customers will also be able to access other company offerings: (1) lab management software, a digital platform to help scientists improve efficiency and processes by automating workflows and connecting lab instruments via the cloud; (2) a customized cell-culture media facility, and (3) a solid-dose formulation facility for optimizing formulations and excipient selection for support to customers in China and globally. Additionally, the center will host a new GMP manufacturing facility offering contract development manufacturing organization services to customers in China and Asia-Pacific.
Source: MilliporeSigma (Switzerland) and MilliporeSigma (China)
